Updated: January 28, 2026
How to Help Your Patients Save Money on Konvomep: A Provider's Guide to Savings Programs
Author
Peter Daggett

- Understanding Konvomep's Cost Landscape
- Program 1: Azurity's Manufacturer Co-Pay Assistance (Best for Commercial Insurance)
- Program 2: Prior Authorization Support
- Program 3: GoodRx and Third-Party Discount Cards
- Program 4: Medicaid and Medicare Pathways
- Program 5: Patient Assistance Programs
- When Cost Is Unavoidable: Clinical Alternatives
- Using medfinder to Help Patients Find and Access Konvomep
- Provider Checklist: Konvomep Cost Reduction Strategies
Overview
Konvomep's retail price can exceed $200 per bottle. This provider's guide covers manufacturer co-pay programs, prior authorization strategies, and patient assistance options.
Is Konvomep in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Konvomep near you.
When you prescribe Konvomep (omeprazole and sodium bicarbonate for oral suspension), cost is a real barrier your patients face. The retail price ranges from approximately $194 to $272 per bottle, and no generic equivalent exists as of 2026. Without insurance coverage or a savings program, many patients will struggle to afford it—and may not fill the prescription at all. This guide walks through every available mechanism to help your patients access Konvomep at an affordable cost.
Understanding Konvomep's Cost Landscape
Konvomep's pricing challenges stem from several factors:
Brand-only product: No generic available, so insurance plans have less incentive to tier it favorably
Specialty formulation: Refrigerated liquid suspensions are more expensive to manufacture and distribute than capsule medications
Insurance tier placement: Many commercial plans place Konvomep on Tier 3 or higher, or require prior authorization, resulting in higher patient cost-sharing
Check live stock now.
Program 1: Azurity's Manufacturer Co-Pay Assistance (Best for Commercial Insurance)
Azurity Pharmaceuticals offers a robust co-pay assistance program that providers should routinely mention when prescribing Konvomep to commercially insured patients.
Patient co-pay as low as $5 per prescription. This applies to eligible commercially insured patients at participating retail pharmacies.
Completely paperless. The program uses eVoucherRx and Voucher on Demand technology, which means savings are applied automatically at the pharmacy counter without a card, coupon, or prior enrollment in most cases. Patients just present their prescription as usual.
Available at virtually all retail pharmacies that participate in the program.
Not available for government programs. The program cannot be used by patients covered by Medicare, Medicaid, TRICARE, or any other federal or state healthcare program.
Action for providers: Include the Azurity co-pay program information on your practice's Konvomep patient education materials. Direct patients to AzuritySolutions.com for program details and eligibility. Note that step-edits and prior authorizations required by the insurance plan still apply even when the co-pay program is used.
Program 2: Prior Authorization Support
For commercially insured patients whose plan requires prior authorization for Konvomep, a successful PA is the most reliable long-term cost reduction tool. Here are evidence-based strategies for efficient PA approvals:
Document the specific clinical need for a liquid formulation. PAs are won by demonstrating medical necessity. The most compelling documentation includes: confirmed dysphagia (ideally with speech pathology evaluation), NG/OG tube in situ, or neurological/structural conditions precluding swallowing of solid dosage forms.
Address step therapy proactively. Many plans require documentation that cheaper alternatives were tried and failed. If your patient attempted Zegerid powder packets or compounded omeprazole suspension and had issues (e.g., cost, preparation difficulty, patient preference), document this in the PA.
Use the FDA-approved indication. Citing Konvomep's specific FDA-approved indications (active benign gastric ulcer, GI bleeding prevention in critically ill) strengthens the medical necessity argument.
Request peer-to-peer review if initially denied. Many first-line PA denials are reversed at peer-to-peer review when the prescribing physician explains the clinical context directly to the plan's medical reviewer.
Program 3: GoodRx and Third-Party Discount Cards
For uninsured patients or those whose insurance does not cover Konvomep, prescription discount cards can provide meaningful savings:
GoodRx: Coupon prices for Konvomep 90 mL start at approximately $197, representing about 18% off the average retail price of $239. Patients access coupons at GoodRx.com or through the GoodRx app.
SingleCare, RxSaver, and similar programs: These platforms may offer comparable or different pricing at various pharmacies. Advise patients to compare prices across multiple cards before filling.
Important note for Medicare patients: Medicare-covered patients cannot use the Azurity co-pay program but can use GoodRx-type coupons when paying out of pocket (not through Medicare Part D). This is patient-specific — advise them to verify with their pharmacist.
Program 4: Medicaid and Medicare Pathways
For patients covered by government programs:
Medicaid: Azurity's prescribing information notes that Konvomep may be covered by Medicaid. State Medicaid formularies vary, so check the patient's state-specific formulary. Some states may require PA for Konvomep even under Medicaid.
Medicare Part D: Coverage varies by plan. As of 2026, the Medicare Part D annual out-of-pocket cap is $2,100. Patients with high-cost specialty medications may benefit from Part D's new catastrophic coverage provisions. Have patients check their plan's Explanation of Benefits or call their Part D plan directly.
Program 5: Patient Assistance Programs
For patients who are uninsured or underinsured and cannot afford Konvomep even with discounts, contact Azurity Pharmaceuticals directly at 844-472-2032 to inquire about patient assistance program availability. You can also direct patients to NeedyMeds.org or RxAssist.org to search for available manufacturer assistance programs.
Found
Rate
on average
When Cost Is Unavoidable: Clinical Alternatives
If a patient cannot afford Konvomep even with all available programs, consider these clinical alternatives:
Zegerid powder packets: Similar mechanism (omeprazole + sodium bicarbonate); generic versions are available at significantly lower cost; available as 20 mg and 40 mg packets
Compounded omeprazole/sodium bicarbonate suspension: Local compounding pharmacies can prepare this at lower cost; not FDA-approved but clinically equivalent formulation concept
Lansoprazole ODT: For patients with mild dysphagia, lansoprazole orally disintegrating tablets dissolve on the tongue and are widely available as generics at low cost
Using medfinder to Help Patients Find and Access Konvomep
Beyond cost, patients also struggle with pharmacy availability. Referring your patients to medfinder.com/providers gives them a tool to find which pharmacies near them have Konvomep in stock, reducing callbacks to your office and helping patients get their medication filled faster.
Provider Checklist: Konvomep Cost Reduction Strategies
Mention Azurity's co-pay program ($5/Rx) at point of prescribing for commercially insured patients
Document medical necessity for liquid formulation clearly for PA submissions
Pursue peer-to-peer review if PA is initially denied
Direct uninsured patients to GoodRx coupons and Azurity's patient assistance number (844-472-2032)
Verify Medicaid coverage for qualifying patients
Have a clinical alternative plan ready for cost-prohibitive cases
Frequently Asked Questions
Azurity Pharmaceuticals' co-pay assistance program allows eligible commercially insured patients to pay as little as $5 per Konvomep prescription at participating retail pharmacies. The program uses paperless technology (eVoucherRx and Voucher on Demand) that is applied automatically at the pharmacy counter without requiring a card or coupon in most cases. It is not available for Medicare, Medicaid, TRICARE, or other government programs.
The most effective Konvomep prior authorization documentation includes: confirmed medical necessity for a liquid PPI formulation (e.g., speech pathology-confirmed dysphagia, NG/OG tube in place, neurological condition affecting swallowing), the FDA-approved indication being treated, documentation of any alternatives tried and failed, and clinical notes explaining why solid dosage forms are inappropriate for this patient.
Azurity Pharmaceuticals may have patient assistance programs for uninsured or underinsured patients. Contact them directly at 844-472-2032 or visit AzuritySolutions.com. Additional resources include NeedyMeds.org and RxAssist.org, which list pharmaceutical manufacturer assistance programs. GoodRx coupons can also reduce costs for cash-paying patients.
The most cost-effective alternatives to Konvomep include: generic Zegerid powder packets (same mechanism, available as generics), compounded omeprazole/sodium bicarbonate suspension from a local compounding pharmacy, or lansoprazole ODT (orally disintegrating tablets) for patients with mild dysphagia. Each should be clinically vetted by the prescriber for the specific patient's needs.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Konvomep also looked for:
More about Konvomep
39,333 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





